COVID-19 UPDATE
A payer appendix listing HCPCS/CPT/Q-codes that require prior authorization, mapping many J-/Q-/S-/Jxxx codes to related entries and occasionally listing brand/generic drug names and other adjunct codes. Also includes Utilization Management voicemail requirements.
No material clinical/coverage changes — appendix enumerates codes requiring prior authorization but has no listed policy changes.
Policy Appendix Summary
This appendix enumerates HCPCS/CPT/Q/J/S codes that require prior authorization under the payer's utilization management program as part of the COVID-19 update package. It is presented as Appendix I and lists numerous J-, Q-, and S-series codes (and other HCPCS/CPT codes) that are subject to authorization requirements.
The file you are viewing is Part 2 of 2 of the appendix set and continues the comprehensive code mappings and listings. Many entries in the appendix map HCPCS codes (including J-, Q-, and S-series) to specific drug or biologic names, cross-referenced internal identifiers, and related codes.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.